Loading stock data…
Fortrea Holdings Inc (FTRE)
$19.52+0.02 (+0.10%)
Market ClosedLast close Jul 24
Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Fortrea Holdings Inc. in the Healthcare sector is trading at $19.52 with a market capitalization of $1.5B. Wall Street consensus targets $17.25 (11 analysts), implying a -11.6% move over the next 12 months. The stock is currently near its 52-week high of $20.19, remaining 45.8% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply -11.6% downside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $636.50M↓ | $660.50M↓ | $701.30M↓ | $710.30M↑ | $651.30M |
| Gross Profit | $123.60M↓ | $131.10M↑ | $122.70M↓ | $133.50M↑ | $116.50M |
| Operating Income | $3.30M↓ | $8.80M↑ | -$3.70M↑ | -$10.90M↑ | -$24.80M |
| Net Income | -$23.60M↑ | -$32.50M↓ | -$15.90M↑ | -$374.90M↑ | -$562.90M |
Peer Comparison
JNJUNHPFE
Fundamentals
Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical pharmacology, such as cl...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.52B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-84.98%
Volume
Today's trading volume
1.34M
Recent News
3 Reasons to Sell FTRE and 1 Stock to Buy Instead
Fortrea trades at $17.93 and has moved in lockstep with the market. Its shares have returned 13.3% over the last six months while the S&P 500 has gained 11.4%.
Fortrea (FTRE) Stock Still Screens Cheap After Its 248% Run
Fortrea Holdings has delivered a 247.6% return over the past year, yet the stock still screens as undervalued on broader valuation checks. This raises a clear question about how much of that rerating is already reflected in the current US$17.76 share price. Over the past 1 year, Fortrea Holdings has returned 247.6%, which puts the recent rally front and center for anyone thinking about the stock today. Future revenue and cash flow expectations can support the current valuation, while any...
Is Fortrea Holdings (FTRE) Overvalued After Its Rally To $17.76?
Fortrea Holdings (FTRE) has drawn fresh attention after recent trading left the stock at $17.76, with short term moves over the past week and month adding context to its longer term performance profile. See our latest analysis for Fortrea Holdings. Over the past year, Fortrea Holdings has seen a sharp shift in sentiment, with a 1 year total shareholder return of 247.55% and a 90 day share price return of 93.46%. However, the 3 year total shareholder return is down 45.39%, suggesting that...
Royalty Pharma PLC (RPRX) Hits Fresh High: Is There Still Room to Run?
Royalty Pharma (RPRX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks Investment Ideas feature highlights: XLV, XBI, LLY, EXEL, PTCT, FTRE and ILMN
Biotech is gaining momentum as healthcare leads higher, with several drugmakers and life sciences companies showing improving earnings trends and breakouts.